Cite
HARVARD Citation
Huang, W. et al. (2013). A Postmarketing Surveillance Study on Erbitux (Cetuximab) in Patients with Metastatic Colorectal Cancer Refractory to Irinotecan-Containing Treatment. Journal of investigative medicine. pp. 1108-1114. [Online].